Medicine, Health & Food

Medicine, Health & Food

Multiple sclerosis in Algeria, a multidisciplinary management at Bejaia University Hospital Center.

Pages: 6  ,  Volume: 54  ,  Issue: 1 , June   2020
Received: 16 Jun 2020  ,  Published: 19 June 2020
Views: 40  ,  Download: 18

Authors

# Author Name
1 F. Bouali
2 S. Khellaf
3 N. Saaoui
4 H. Meziani
5 D. Si Ahmed

Abstract

The aim of our study is to establish the clinical, para-clinical, therapeutic and progressive profile of Multiple sclerosis (MS) in the Algerian region of Bejaia. We performed a retrospective descriptive study for a period of 4 years, going from January 2015 to December 2018. Diagnosis of MS was retained according to the 2010 McDonald criteria. Epidemiological characteristics were studied, such as first clinical presentation, clinical form, biological and neuroradiological data, current therapeutic management as well as evolutionary profile by evaluation of the Expanded Disability Status Scale (EDSS). We collected 109 Patient with MS, including 71 (65%) women and 38 (35%) men with a Sex Ratio F / M of 1.86. Average age of patients was 38.7 years with extremes between 17 and 65 years. Average age of onset was 31 years (ranging from 11 to 53 years). MS diagnostic delay was 2.9 years. The most frequent MS form was the relapsing remitting (80%), then the secondary progressive (12%) and finally the primary progressive form in 8% of cases. Patients received relapses corticosteroid treatment in 73% of cases. Disease modifying therapies (DMT) was prescribed based on interferon beta in 83 patients, Natalizumab in 2 patients and cyclophosphamide in 22 patients. We observed that EDSS increased from less than 5 in all patients at onset to more than 5 in 11% of patients after an average period of 6.7 years. Despite the small sample of our population, the severe aspect of North African MS could be clearly seen in our study.

Keywords

  • North Africa
  • Multiple Sclerosis
  • Disabilities
  • References

    1. Compston, A. and A. Coles, Multiple sclerosis. Lancet, 2008. 372(9648): p. 1502-17.

    2. Brochet, B., et al., Chapitre 1 - Signes et symptômes de la sclérose en plaques, in La Sclérose en Plaques - Clinique et Thérapeutique, B. Brochet, et al., Editors. 2017, Elsevier Masson: Paris. p. 3-78.

    3. Feinstein, A., et al., Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry, 1992. 55(10): p. 869-76.

    4. Filippi, M., et al., Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry, 2000. 68(2): p. 157-61.

    5. Poser, C.M., et al., New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 1983. 13(3): p. 227-231.

    6. McDonald, W.I., et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 2001. 50(1): p. 121-127.

    7. Thompson, A.J., et al., Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 2018. 17(2): p. 162-173.

    8. Fazekas, F., et al., The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology, 1999. 53(3): p. 448-448.

    9. Filippi, M., et al., MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. The Lancet Neurology, 2016. 15(3): p. 292-303.

    10. Cortese, R., et al., Advances in brain imaging in multiple sclerosis. Ther Adv Neurol Disord, 2019. 12: p. 1756286419859722.

    11. Correale, J. and M.d.l.M.B. Molinas, Oligoclonal bands and antibody responses in multiple sclerosis. Journal of neurology, 2002. 249(4): p. 375-389.

    12. Pantazou, V., M. Schluep, and R. Du Pasquier, Environmental factors in multiple sclerosis. Presse Med, 2015. 44(4 Pt 2): p. e113-20.

    13. Pugliatti, M., et al., Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl, 2008. 188: p. 34-40.

    14. Ebers, G.C., Environmental factors and multiple sclerosis. Lancet Neurol, 2008. 7(3): p. 268-77.

    15. Vermersch, P., Advances in the management of MS symptoms: recently proposed clinical management algorithms. Neurodegener Dis Manag, 2015. 5(6 Suppl): p. 23-6.

    16. Brassat, D., [Pathophysiology of multiple sclerosis]. Presse Med, 2010. 39(3): p. 341-8.

    17. Koch-Henriksen, N. and P.S. Sorensen, Why does the north–south gradient of incidence of multiple sclerosis seem to have disappeared on the Northern hemisphere? Journal of the neurological sciences, 2011. 311(1-2): p. 58-63.

    18. Simpson, S., et al., Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry, 2011. 82(10): p. 1132-1141.

    19. Thibault Moreau, R.D.P., Sclérose en plaques. Editions John Libbey Eurotext ed, ed. Doin. 2017: John Libbey Eurotext.

    20. Warren, S.A., L.W. Svenson, and K.G. Warren, Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada. Mult Scler, 2008. 14(7): p. 872-9.

    21. Hader, W.J. and I.M. Yee, Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan. Neurology, 2007. 69(12): p. 1224-9.

    22. Barnett, M.H., et al., Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J Neurol Sci, 2003. 213(1-2): p. 1-6.

    23. Orton, S.M., et al., Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol, 2006. 5(11): p. 932-6.

    24. Trojano, M., et al., Geographical variations in sex ratio trends over time in multiple sclerosis. PloS one, 2012. 7(10): p. e48078-e48078.

    25. Alonso, A. and M.A. Hernán, Temporal trends in the incidence of multiple sclerosis. A systematic review, 2008. 71(2): p. 129-135.

    26. Heydarpour, P., et al., Multiple Sclerosis Epidemiology in Middle East and North Africa: A Systematic Review and Meta-Analysis. Neuroepidemiology, 2015. 44(4): p. 232-44.

    27. Z. Bedrane-Barka, prevalence, formes cliniques, evolution, et traitement de la sclerose en plaques dans la region de Tlemcen, in Thèse de DSM. 2013.

    28. Drai, R., Etude clinique et Profil évolutif des patients suivis pour une Sclérose en plaques au niveau du CHU de Blida, avec une estimation de la prévalence dans la commune de Blida. , in Thèse de DSM,. 2018.

    29. Beeson, P.B., Age and sex associations of 40 autoimmune diseases. Am J Med, 1994. 96(5): p. 457-62.

    30. Milo, R. and E. Kahana, Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev, 2010. 9(5): p. A387-94.

    31. Duquette, P., et al., The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci, 1992. 19(4): p. 466-71.

    32. Sellner, J., et al., The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors. Autoimmun Rev, 2011. 10(8): p. 495-502.

    33. Visscher, B.R., et al., Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta neurologica scandinavica, 1984. 70(5): p. 321-328.

    34. Runmarker, B., et al., Prediction of outcome in multiple sclerosis based on multivariate models. Journal of neurology, 1994. 241(10): p. 597-604.

    35. Weinshenker, B.G., Natural history of multiple sclerosis. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 1994. 36(S1): p. S6-S11.

    36. Trojano, M., et al., Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. Journal of Neurology, Neurosurgery & Psychiatry, 1995. 58(3): p. 300-306.

    37. Moreau, T. and C. Confavreux, Can the prognosis of multiple sclerosis be predicted? Pathologie-biologie, 2000. 48(2): p. 132-138.

    38. Ligouri, M., et al., Age at onset in multiple sclerosis. Neurological Sciences, 2000. 21(2): p. S825-S829.

    39. Kister, I., et al., Natural history of multiple sclerosis symptoms. International journal of MS care, 2013. 15(3): p. 146-156.

    40. Hecham, N., et al., Multiple sclerosis: progression rate and severity in a multicenter cohort from Algeria. Mult Scler, 2014. 20(14): p. 1923-4.

    41. Araqi-Houssaini, A., et al., Multiple sclerosis severity score in a cohort of Moroccan patients. Mult Scler, 2014. 20(6): p. 764-5.

    42. Debouverie, M., et al., More severe disability of North Africans vs Europeans with multiple sclerosis in France. Neurology, 2007. 68(1): p. 29-32.